BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25248853)

  • 1. Heterogeneity in [18F]fluorodeoxyglucose positron emission tomography/computed tomography of non-small cell lung carcinoma and its relationship to metabolic parameters and pathologic staging.
    van Gómez López O; García Vicente AM; Honguero Martínez AF; Soriano Castrejón AM; Jiménez Londoño GA; Udias JM; León Atance P
    Mol Imaging; 2014; 13():. PubMed ID: 25248853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity in [¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography of non-small cell lung carcinoma and its relationship to metabolic parameters and pathologic staging.
    van Gómez López O; García Vicente AM; Honguero Martínez AF; Soriano Castrejón ÁM; Jiménez Londoño GA; Udias JM; León Atance P
    Mol Imaging; 2014; 13():. PubMed ID: 25742961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
    Koh YW; Lee SJ; Park SY
    Lung Cancer; 2017 Feb; 104():31-37. PubMed ID: 28212997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
    Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y
    Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
    Zhao SJ; Wu N; Zheng R; Liu Y; Zhang WJ; Liang Y; Zhang H; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):754-7. PubMed ID: 24378097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
    Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
    Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma.
    Kim DH; Song BI; Hong CM; Jeong SY; Lee SW; Lee J; Ahn BC
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2051-7. PubMed ID: 24990401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer.
    Meng X; Sun X; Mu D; Xing L; Ma L; Zhang B; Zhao S; Yang G; Kong FM; Yu J
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):960-6. PubMed ID: 21440998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheral non-small cell lung cancer.
    Park SY; Yoon JK; Park KJ; Lee SJ
    Cancer Imaging; 2015 Dec; 15():21. PubMed ID: 26694918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
    Sahiner I; Atasever T; Akdemir UO; Ozturk C; Memis L
    Rev Esp Med Nucl Imagen Mol; 2013; 32(6):357-63. PubMed ID: 23747221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Texture features of primary tumor on
    Aydos U; Ünal ER; Özçelik M; Akdemir D; Ekinci Ö; Taştepe Aİ; Memiş L; Atay LÖ; Akdemir ÜÖ
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(6):343-350. PubMed ID: 34752367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between FDG-PET/CT findings and solid type non-small cell cancer prognostic factors: are there differences between adenocarcinoma and squamous cell carcinoma?
    Ito R; Iwano S; Kishimoto M; Ito S; Kato K; Naganawa S
    Ann Nucl Med; 2015 Dec; 29(10):897-905. PubMed ID: 26342592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of Metabolic Tumor Volume and Total Lesion Glycolysis to Predict Prognosis in Early-Stage Lung Cancer at Preoperative Staging.
    Karaman E; Goksel S; Tuluce K
    J Coll Physicians Surg Pak; 2022 Jun; 32(6):740-745. PubMed ID: 35686405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.